Skip to content

Prevention of incisional hernia in high-risk patients with prophylactic slowly-resorbable TIGR® Matrix mesh in midline laparotomies.

Prevention of incisional hernia in high-risk patients with prophylactic slowly-resorbable TIGR® Matrix mesh in midline laparotomies.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22803
Enrollment
70
Registered
2019-07-29
Start date
2019-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of incisional hernia in high-risk patients

Interventions

Patients with an AAA undergoing an elective midline laparotomy will receive closure of the fascia with the aid of a prosthetic mesh. Patients will receive prophylactic mesh augmentation with synthetic

Sponsors

Novus Scientific AB, Uppsala Sweden
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Elective midline laparotomy for patients with Abdominal Aortic Aneurysm. - Age = 18 years. - Signed informed consent by patient.

Exclusion criteria

Exclusion criteria: - Pregnancy. - Emergency procedures. - Inclusion in other trials with interference of the primary endpoint. - Life expectancy less than 24 months (as estimated by the attending physician). - Immune suppression therapy within 2 weeks before surgery.

Design outcomes

Primary

MeasureTime frame
The primary objective is to examine the effectiveness of incisional hernia prevention with synthetic, slowly-resorbable TIGR® Matrix mesh placement in patients with AAA undergoing midline laparotomy.

Secondary

MeasureTime frame
The secondary objectives are to measure relevant postoperative complications, postoperative pain, sensitivity of the skin in the area of the mesh placement and quality of life.

Contacts

Public ContactGijs de Smet

Erasmus MC, University Medical Center

g.h.j.desmet@erasmusmc.nl0107043683

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)